BUDGET IMPACT ANALYSIS OF RITLECTINIB FOR TREATMENT OF ALOPECIA AREATA IN A TERTIARY GOVERNMENT HOSPITAL IN RIYADH
Author(s)
Saif AlHawwashi, BSc, MSc1, Abdullah M. Alshahrani, BSc, MSc2, Najla H. Alshamrani, PharmD3;
1SECURITY FORCES HOSPITAL, Pharmacoeconomics Consultant, Riyadh, Saudi Arabia, 2Armed Forces Hospital Southern Region, Saudi Arabia, Khamis Mushait, Saudi Arabia, 3Security Forces Hospital, Riyadh, Saudi Arabia
1SECURITY FORCES HOSPITAL, Pharmacoeconomics Consultant, Riyadh, Saudi Arabia, 2Armed Forces Hospital Southern Region, Saudi Arabia, Khamis Mushait, Saudi Arabia, 3Security Forces Hospital, Riyadh, Saudi Arabia
OBJECTIVES: Estimate the 3-year pharmacy budget impact analysis of replacing the current comparator regimen with Ritlectinib for treatment of Alopecia Areata in a tertiary government hospital in Riyadh.
METHODS: budget impact model from the pharmacy perspective. Inputs: drug acquisition, annual diagnostic tests, follow-up consultation, and monitoring tests (including extra monitoring for baricitinib). Time horizon = 3 years. Two cohort approaches: fixed (30 patients) and growing (4% p.a.). Scenarios: 0%, 25%, 50%, 75%, 100% constant uptake and a 25→50→75% ramp.
RESULTS: Ritlectinib is less costly per patient-year (40,920 SAR) than the comparator (60,136.25 SAR). Switching all patients immediately to ritlectinib yields 3-year cumulative savings 1,729,462.50 SAR for the fixed cohort. Savings increase slightly if cohort grows (4% p.a).
CONCLUSIONS: The Budget Impact Analysis demonstrates that adding of Retlectinib to the hospital formulary is cost-saving from the pharmacy prespective, resulting in a net reduction in drug expenditure while maintaining appropriate therapeutic outcomes
METHODS: budget impact model from the pharmacy perspective. Inputs: drug acquisition, annual diagnostic tests, follow-up consultation, and monitoring tests (including extra monitoring for baricitinib). Time horizon = 3 years. Two cohort approaches: fixed (30 patients) and growing (4% p.a.). Scenarios: 0%, 25%, 50%, 75%, 100% constant uptake and a 25→50→75% ramp.
RESULTS: Ritlectinib is less costly per patient-year (40,920 SAR) than the comparator (60,136.25 SAR). Switching all patients immediately to ritlectinib yields 3-year cumulative savings 1,729,462.50 SAR for the fixed cohort. Savings increase slightly if cohort grows (4% p.a).
CONCLUSIONS: The Budget Impact Analysis demonstrates that adding of Retlectinib to the hospital formulary is cost-saving from the pharmacy prespective, resulting in a net reduction in drug expenditure while maintaining appropriate therapeutic outcomes
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE402
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)